Literature DB >> 3487553

Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

A J Morrison, K K Hoffmann, R P Wenzel.   

Abstract

We studied the spectrum of clinical disease in 99 patients with nosocomial Pseudomonas maltophilia isolates at the University of Virginia Hospital from 1981 through 1984. The annual rate of isolation increased from 7.1 to 14.1 per 10,000 patient discharges. A crude mortality rate of 43% was documented in all patients from whom the organism was cultured, and the data include 12 patients with nosocomial bacteremia (four deaths). Risk factors associated with death for patients having a P. maltophilia isolate included the following: requirement for care in any intensive care unit during hospitalization (P = 0.0001), patient age over 40 years (P = 0.002), and a pulmonary source for the P. maltophilia isolate (P = 0.003). All P. maltophilia isolates were susceptible to trimethoprim-sulfamethoxazole, 60% of the isolates were resistant to all aminoglycosides (amikacin, tobramycin, and gentamicin), and more than 75% of the isolates were resistant to all beta-lactam antibiotics. The antibiotic susceptibility pattern allows for a niche exploitable in the hospital microbial environment by an organism with a marked associated mortality.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487553      PMCID: PMC268830          DOI: 10.1128/jcm.24.1.52-55.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Prosthetic valve endocarditis. Analysis of 38 cases.

Authors:  W E Dismukes; A W Karchmer; M J Buckley; W G Austen; M N Swartz
Journal:  Circulation       Date:  1973-08       Impact factor: 29.690

2.  Acute mastoiditis following pseudomonas maltophilia infection: case report.

Authors:  H D Harlowe
Journal:  Laryngoscope       Date:  1972-05       Impact factor: 3.325

3.  Gram-negative bacteria isolated from external eye infections.

Authors:  T Ben-Tovim; E Eylan; A Romano; R Stein
Journal:  Infection       Date:  1974       Impact factor: 3.553

4.  Disc sensitivity as an aid in the identification of some gram-negative non-fermentative rods.

Authors:  A Von Graevenitz; J J Redys
Journal:  Health Lab Sci       Date:  1968-04

5.  Infrequently encountered Pseudomonas species causing infection in humans.

Authors:  G L Gilardi
Journal:  Ann Intern Med       Date:  1972-08       Impact factor: 25.391

6.  Nonfermentative gram-negative bacilli of nosocomial interest.

Authors:  P Gardner; W B Griffin; M N Swartz; L J Kunz
Journal:  Am J Med       Date:  1970-06       Impact factor: 4.965

7.  Nonfermentative bacilli associated with man. 3. Pathogenicity and antibiotic susceptibility.

Authors:  M M Pedersen; E Marso; M J Pickett
Journal:  Am J Clin Pathol       Date:  1970-08       Impact factor: 2.493

8.  Pseudomonas maltophilia infections in man.

Authors:  G L Gilardi
Journal:  Am J Clin Pathol       Date:  1969-01       Impact factor: 2.493

9.  Bacteremia with and without meningitis due to Yersinia enterocolitica, Edwardsiella tarda, Comamonas terrigena, and Pseudomonas maltophilia.

Authors:  A C Sonnenwirth
Journal:  Ann N Y Acad Sci       Date:  1970-10-30       Impact factor: 5.691

10.  Bacterial endocarditis following open-heart surgery.

Authors:  T J Yeh; I N Anabtawi; V E Cornett; A White; W H Stern; R G Ellison
Journal:  Ann Thorac Surg       Date:  1967-01       Impact factor: 4.330

View more
  28 in total

1.  Is the prevalence of Stenotrophomonas maltophilia isolation and nosocomial infection increasing in intensive care units?

Authors:  E Meyer; F Schwab; P Gastmeier; H Rüden; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-11       Impact factor: 3.267

2.  Prevalence of serotypes of Xanthomonas maltophilia from world-wide sources.

Authors:  B Schable; D L Rhoden; W R Jarvis; J M Miller
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

3.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 5.  Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  R G Munter; A M Yinnon; Y Schlesinger; C Hershko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

6.  Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  J D Yao; M Louie; L Louie; J Goodfellow; A E Simor
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

7.  Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment.

Authors:  F P Laing; K Ramotar; R R Read; N Alfieri; A Kureishi; E A Henderson; T J Louie
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

8.  Diversity of nosocomial Xanthomonas maltophilia (Stenotrophomonas maltophilia) as determined by ribotyping.

Authors:  P Gerner-Smidt; B Bruun; M Arpi; J Schmidt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

9.  Molecular typing of Stenotrophomonas (Xanthomonas) maltophilia by DNA macrorestriction analysis and random amplified polymorphic DNA analysis.

Authors:  J D Yao; J M Conly; M Krajden
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

10.  Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.